NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$64.8b

Last Updated

2021/05/15 23:53 UTC

Data Sources

Company Financials +

Executive Summary

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. More Details


Snowflake Analysis

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has Moderna's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MRNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: MRNA's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

-1.1%

MRNA

-0.4%

US Biotechs

-1.7%

US Market


1 Year Return

142.0%

MRNA

19.8%

US Biotechs

50.8%

US Market

Return vs Industry: MRNA exceeded the US Biotechs industry which returned 19.2% over the past year.

Return vs Market: MRNA exceeded the US Market which returned 50.5% over the past year.


Shareholder returns

MRNAIndustryMarket
7 Day-1.1%-0.4%-1.7%
30 Day0.9%-0.8%-1.5%
90 Day-12.2%-10.3%0.4%
1 Year142.0%142.0%21.6%19.8%53.3%50.8%
3 Yearn/a24.3%17.9%61.5%51.4%
5 Yearn/a49.2%37.8%125.8%100.7%

Long-Term Price Volatility Vs. Market

How volatile is Moderna's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Moderna undervalued compared to its fair value and its price relative to the market?

106.09x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: MRNA ($161.38) is trading above our estimate of fair value ($53.09)

Significantly Below Fair Value: MRNA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MRNA is poor value based on its PE Ratio (106.1x) compared to the US Biotechs industry average (26x).

PE vs Market: MRNA is poor value based on its PE Ratio (106.1x) compared to the US market (19.9x).


Price to Earnings Growth Ratio

PEG Ratio: MRNA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: MRNA is overvalued based on its PB Ratio (16.9x) compared to the US Biotechs industry average (3.4x).


Future Growth

How is Moderna forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

-54.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRNA's earnings are forecast to decline over the next 3 years (-54% per year).

Earnings vs Market: MRNA's earnings are forecast to decline over the next 3 years (-54% per year).

High Growth Earnings: MRNA's earnings are forecast to decline over the next 3 years.

Revenue vs Market: MRNA's revenue is expected to decline over the next 3 years (-23.3% per year).

High Growth Revenue: MRNA's revenue is forecast to decline over the next 3 years (-23.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MRNA's Return on Equity is forecast to be low in 3 years time (5.6%).


Past Performance

How has Moderna performed over the past 5 years?

-2.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MRNA has high quality earnings.

Growing Profit Margin: MRNA became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: MRNA has become profitable over the past 5 years, growing earnings by -2.4% per year.

Accelerating Growth: MRNA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MRNA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (1.6%).


Return on Equity

High ROE: MRNA's Return on Equity (15.6%) is considered low.


Financial Health

How is Moderna's financial position?


Financial Position Analysis

Short Term Liabilities: MRNA's short term assets ($11.7B) exceed its short term liabilities ($8.4B).

Long Term Liabilities: MRNA's short term assets ($11.7B) exceed its long term liabilities ($415.0M).


Debt to Equity History and Analysis

Debt Level: MRNA is debt free.

Reducing Debt: MRNA had no debt 5 years ago.

Debt Coverage: MRNA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MRNA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Moderna current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MRNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MRNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MRNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Stephane Bancel (47 yo)

9.58yrs

Tenure

US$12,855,275

Compensation

Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel serves as a Special Partner at Flagship Pioneering since F...


CEO Compensation Analysis

Compensation vs Market: Stephane's total compensation ($USD12.86M) is about average for companies of similar size in the US market ($USD11.16M).

Compensation vs Earnings: Stephane's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MRNA's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: MRNA's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MRNA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.2%.


Top Shareholders

Company Information

Moderna, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moderna, Inc.
  • Ticker: MRNA
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$64.799b
  • Shares outstanding: 401.53m
  • Website: https://www.modernatx.com

Number of Employees


Location

  • Moderna, Inc.
  • 200 Technology Square
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Biography

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 23:53
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.